Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on October 30, 2009. The report discloses a significant legal development involving a Multi-State Intervention Complaint filed in the United States District Court for the District of Massachusetts. The complaint names the Company, along with Amgen Inc., as defendants in a civil case concerning alleged violations of federal and state health laws.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal contingency and does not contain financial performance data.
Material Changes and Legal Allegations
On October 30, 2009, fourteen states and the District of Columbia intervened in a pending qui tam civil case. The allegations, covering the period from 2002 through 2009, assert that:
- Amgen offered illegal remuneration to medical providers to increase prescriptions of the anemia drug Aranesp.
- AmerisourceBergen business units, specifically ASD Specialty Healthcare, Inc. and International Nephrology Network (INN), conspired with Amgen to promote Aranesp in violation of health laws.
- Defendants caused medical providers to submit false medical certifications and false claims for payment to state Medicaid programs and federal programs like Medicare.
Prior to this intervention, the Company had not received a subpoena from the New York Attorney General or other state offices, though it had received a subpoena from the Department of Justice (DOJ) on June 22, 2009, and has been cooperating with the investigation.
Outlook, Risks, and Management Commentary
Management states the Company intends to defend itself vigorously against the allegations. The Company cannot predict the outcome of the civil action or the ongoing DOJ investigation. The filing highlights significant risks, including potential criminal, civil, and administrative liability. Consequences could include:
- Significant financial damages.
- Criminal and civil penalties.
- Exclusion from participation in federal health programs.
Investor Verification Checklist
- Verify the current status of the DOJ investigation and the Multi-State Intervention Complaint.
- Assess the potential financial exposure related to False Claims Act violations and Medicaid/Medicare fraud allegations.
- Monitor for any future subpoenas or requests for information from state attorney general offices.
- Review the Company's historical disclosures regarding the Aranesp promotion and related business units (ASD and INN).